Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twice-daily Insulin degludec/insulin aspart vs four-times-daily detemir + aspart in newly diagnosed type 2 diabetes mellitus
ChiCTR2100042914Phase 4Recruiting
- Sponsor
- Xichang People's Hospital
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of insulin degludec, insulin aspart and insulin detemir in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Xichang People's Hospital. Primary endpoints: fasting blood-glucose, postprandial blood sugar (2-hour post-meal) and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
insulin degludecinsulin aspartinsulin detemir
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100042914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042914.